Antibodies specific for sclerostin and methods for increasing bone mineralization
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C12N-015/00
C12N-015/09
C12N-015/13
C12N-015/63
출원번호
US-0592116
(2012-08-22)
등록번호
US-8563271
(2013-10-22)
발명자
/ 주소
Winkler, David G.
Shi, Jiye
Latham, John
출원인 / 주소
UCB Manufacturing, Inc.
대리인 / 주소
Marshall, Gerstein & Borun LLP
인용정보
피인용 횟수 :
1인용 특허 :
54
초록▼
Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member
Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
대표청구항▼
1. An isolated polynucleotide encoding an antibody, or antigen binding fragment thereof, that specifically binds to an epitope of amino acids 86-111 of SEQ ID NO: 1. 2. The polynucleotide of claim 1, wherein the antibody, or antigen-binding fragment thereof, specifically binds to an epitope of amino
1. An isolated polynucleotide encoding an antibody, or antigen binding fragment thereof, that specifically binds to an epitope of amino acids 86-111 of SEQ ID NO: 1. 2. The polynucleotide of claim 1, wherein the antibody, or antigen-binding fragment thereof, specifically binds to an epitope of amino acids 86-105 of SEQ ID NO: 1. 3. The polynucleotide of claim 1, wherein the antibody, or antigen-binding fragment thereof, specifically binds to an epitope of amino acids 96-111 of SEQ ID NO: 1. 4. The polynucleotide of claim 1, wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody. 5. The polynucleotide of claim 1, wherein the antibody is an antigen-binding fragment. 6. The polynucleotide of claim 1, wherein the antibody comprises an antigen-binding fragment selected from the group consisting of F(ab′)2, Fab, Fab′, Fd, and Fv. 7. The polynucleotide of claim 1, wherein the antibody comprises an Fv fragment. 8. The polynucleotide of claim 1, wherein the antibody comprises a single chain antibody. 9. The polynucleotide of claim 1, wherein the antibody comprises at least one heavy chain and at least one light chain. 10. An isolated polynucleotide encoding an antibody, or antigen binding fragment thereof, that binds to a peptide consisting of amino acids 86-111 of SEQ ID NO: 1 with an affinity (Kd) of less than or equal to about 10−7 M. 11. The polynucleotide of claim 10, wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody. 12. The polynucleotide of claim 10, wherein the antibody, or an antigen-binding fragment thereof, binds to a peptide consisting of amino acids 86-105 of SEQ ID NO: 1. 13. The polynucleotide of claim 12, wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody. 14. The polynucleotide of claim 10, wherein the antibody is an antigen-binding fragment. 15. The polynucleotide of claim 10, wherein the antibody comprises at least one heavy chain and at least one light chain. 16. An isolated polynucleotide encoding a heavy chain of an antibody, or antigen binding fragment thereof, that specifically binds to an epitope of amino acids 86-111 of SEQ ID NO: 1. 17. An isolated polynucleotide encoding a light chain of an antibody, or antigen binding fragment thereof, that specifically binds to an epitope of amino acids 86-111 of SEQ ID NO: 1. 18. An isolated polynucleotide encoding a heavy chain of an antibody, or antigen binding fragment thereof, that specifically binds to a peptide consisting of amino acids 86-111 of SEQ ID NO: 1. 19. An isolated polynucleotide encoding a light chain of an antibody, or antigen binding fragment thereof, that specifically binds to a peptide consisting of amino acids 86-111 of SEQ ID NO: 1. 20. A vector comprising the polynucleotide of any one of claims 1-19, operably linked to a transcriptional or translational regulatory element. 21. A host cell comprising the polynucleotide of any of claims 1-19. 22. A host cell comprising a polynucleotide encoding a heavy chain of an antibody, or antigen binding fragment thereof, that specifically binds to an epitope of amino acids 86-111 of SEQ ID NO: 1 and a polynucleotide encoding a light chain of an antibody, or antigen binding fragment thereof, that specifically binds to an epitope of amino acids 86-111 of SEQ ID NO: 1. 23. A host cell comprising a polynucleotide encoding a heavy chain of an antibody, or antigen binding fragment thereof, that specifically binds to a peptide consisting of amino acids 86-111 of SEQ ID NO: 1 and a polynucleotide encoding a light chain of an antibody, or antigen binding fragment thereof, that specifically binds to a peptide consisting of amino acids 86-111 of SEQ ID NO: 1. 24. A host cell comprising a vector of claim 20. 25. A method of producing an antibody comprising the step of culturing the host cell of claim 21 and isolating the antibody produced therefrom. 26. A method of producing an antibody comprising the step of culturing the host cell of claim 22 and isolating the antibody produced therefrom. 27. A method of producing an antibody comprising the step of culturing the host cell of claim 23 and isolating the antibody produced therefrom. 28. A method of producing an antibody comprising the step of culturing the host cell of claim 24 and isolating the antibody produced therefrom.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (54)
Btzow Ralf (Helsinki CA FIX) Ruoslahti Erkki (Rancho Santa Fe CA), 60 kDa transforming growth factor-b
상세보기
Brunkow, Mary E.; Galas, David J.; Kovacevich, Brian; Mulligan, John T.; Paeper, Bryan W.; Van Ness, Jeffrey; Winkler, David G., Antibodies associated with alterations in bone density.
Brunkow, Mary E; Galas, David J; Kovacevich, Brian; Mulligan, John T; Paeper, Bryan W; Van Ness, Jeffrey; Winkler, David G, Antibodies associated with alterations in bone density.
Dan Michael D.,CAX ; Maiti Pradip K.,CAX ; Kaplan Howard A.,CAX, Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers.
Brunkow, Mary E; Galas, David J; Kovacevich, Brian; Mulligan, John T; Paeper, Bryan; Van Ness, Jeffrey; Winkler, David G, Compositions and methods for increasing bone mineralization.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Compositions and methods for increasing bone mineralization.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Yagi Kunio (Aichi-ken JPX) Noda Hitoshi (Aichi-ken JPX) Ohishi Nobuko (Gifu JPX) Kurono Masayasu (Mie-ken JPX), Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation.
Stemmer Willem P. C. ; Crameri Andreas, Methods for generating polynucleotides having desired characteristics by iterative selection and recombination.
Margolis David J. (Philadelphia PA), Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Nucleic acids encoding a novel family of TGF-.beta. binding proteins from humans.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Polypeptides associated with alterations in bone density.
Tsuchiya Masayuki,GB3 ; Sato Koh,GB3 ; Bendig Mary Margaret,GB3 ; Jones Steven Tarran,GB3 ; Saldanha Jose William,GB3, Reshaped human to human interleukin-6 receptor.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Goldenberg Milton D. (11837 Gainsborough Rd. Potomac MD 20854), Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.